Sign inJoin waitlistJoin the waitlist

Tuan Vu

Professor and Program Director · University of South Florida Morsani College of Medicine

Credentials: · · · · · ·

History

1996–1997
Columbia Presbyterian Medical Center of New York
1995–1996
Columbia Presbyterian Medical Center of New York
1990–1993
Penn State Milton S Hershey Medical Center
1989–1990
Penn State College of Medicine
1985–1989

Research

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
The Lancet Neurology · 2021 · 608 citations
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
New England Journal of Medicine · 2020 · 415 citations
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase…
The Lancet Neurology · 2023 · 236 citations

James Howard
29 papers
Kurenai Tanji
14 papers · 7 as a resident
Michio Hirano
13 papers
Clifton Gooch
11 papers
Andrea Swenson
10 papers
Chafic Karam
10 papers
James Wymer
10 papers
Shafeeq Ladha
10 papers
Ali Habib
9 papers
Carlayne Jackson
9 papers
Jim Caress
9 papers
Namita Goyal
9 papers

Clinical trials

Efgartigimod for Stiff Person Syndrome (ESPS)
Principal investigator · Not yet recruiting · Phase 2
University of South Florida
2025–2027
Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Principal investigator · Completed
University of South Florida
2014–2021
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Principal investigator · Completed
University of South Florida
2011–2014
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Site PI · Recruiting · Phase 1, Phase 2
Sanofi
2025–2032